Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04586426
What this trial is testing

The Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 228
Early research (Phase 1)Looking for participantsNCT06178614
What this trial is testing

JNJ-87890387 for Advanced Solid Tumors

Who this might be right for
NeoplasmsAdvanced Solid Tumors
Janssen Research & Development, LLC 200
Testing effectiveness (Phase 2)Looking for participantsNCT07299747
What this trial is testing

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Who this might be right for
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc 255
Testing effectiveness (Phase 2)Looking for participantsNCT06635785
What this trial is testing

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
OncoC4, Inc. 387
Testing effectiveness (Phase 2)Study completedNCT02570308
What this trial is testing

The Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Who this might be right for
Uveal Melanoma
Immunocore Ltd 146
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Testing effectiveness (Phase 2)Ended earlyNCT04750239
What this trial is testing

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Who this might be right for
SCLC
Y-mAbs Therapeutics 3
Early research (Phase 1)Not Yet RecruitingNCT07619001
What this trial is testing

Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations

Who this might be right for
Healthy Male Adults Participants
Akeso 158
Testing effectiveness (Phase 2)Study completedNCT03852251
What this trial is testing

AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaAdvanced Solid TumorsGastroesophageal Junction Adenocarcinoma
Akeso 338
Early research (Phase 1)WithdrawnNCT00521261
What this trial is testing

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07449156
What this trial is testing

Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

Who this might be right for
Acne Vulgaris
Shanghai Huaota Biopharmaceutical Co., Ltd. 21
Testing effectiveness (Phase 2)Looking for participantsNCT07172802
What this trial is testing

GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer (NSCLC)+3 more
GI Innovation, Inc. 102
Testing effectiveness (Phase 2)Study completedNCT04696809
What this trial is testing

Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematologic Malignancies
Janssen Pharmaceutical K.K. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT06097364
What this trial is testing

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Who this might be right for
Follicular Lymphoma (FL)
Regeneron Pharmaceuticals 733
Testing effectiveness (Phase 2)Study completedNCT00352833
What this trial is testing

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Who this might be right for
Gastric CancerGastric Adenocarcinoma
Neovii Biotech 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07567014
What this trial is testing

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Who this might be right for
Multiple MyelomaLarge B-cell Lymphoma (LBCL)
NYU Langone Health 60
Early research (Phase 1)Looking for participantsNCT04104607
What this trial is testing

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Who this might be right for
Castration-Resistant Prostatic Cancer
University Hospital Tuebingen 86
Testing effectiveness (Phase 2)Looking for participantsNCT07448116
What this trial is testing

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Advanced Tumor
Betta Pharmaceuticals Co., Ltd. 164
Early research (Phase 1)UnknownNCT04662099
What this trial is testing

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Who this might be right for
CS1+ or BCMA+ Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 24
Post-approval studies (Phase 4)Not Yet RecruitingNCT07689149
What this trial is testing

Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%

Who this might be right for
Kidney Transplantation RecipientsHLA Sensitization
West China Hospital 20
Next Page